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Summary 
Activation of T  cell hybridomas induces a G1/S  cell cycle block and apoptosis.  We isolated a 
variant of the 2B4.11 T  cell hybridoma that, when activated via the TCR, produced IL-2 and 
underwent growth inhibition but did not die.  Analysis of a variety of cell surface molecules 
revealed that the variant cell line,  termed VDI,  expressed very low levels of Fas compared to 
the wild type cells. Unlike 2B4.11 cells, VD1 cells were not killed by Fas ligand (FasL)-bearing 
effector ceils. To determine if Fas is involved in activation-induced apoptosis, two different re- 
agents that specifically bind Fas without killing the T cell hybridomas, a monoclonal antibody 
and a soluble Fas:Fc chimeric molecule, were added to activated T cell hybridomas. Both treat- 
ments prevented activation-induced apoptosis in a dose-dependent manner, but had no effect 
on IL-2 production or growth inhibition. Northern blot analysis revealed that unactivated 2B4.11 
cells expressed negligible levels of FasL mRNA, but transcripts were detectable as early as 2 h 
after activation and continued to increase up to 4-6 h after activation. Anti-TCR induced activa- 
tion of 2B4.11 cells in the presence of a TCR-  2B4.11 variant resulted in death of the unacti- 
rated "bystander" cells, which was inhibited by anti-Fas antibodies. Finally, treatment of T hybridoma 
cells with 9-cis retinoic acid or glucocorticoids, which are known to prevent activation-induced 
T cell apoptosis, inhibited the up-regulation of FasL. We conclude that up-regulated expression 
of FasL and its subsequent interaction with Fas accounts for the apoptotic response of T  cell 
hybridomas to activation, and that retinoic acid and corticosteroids inhibit activation-induced 
apoptosis by preventing up-regulation of FasL. 
T  lymphocytes undergo apoptosis in response to a variety 
of stimuli, including glucocorticoids, radiation, with- 
drawal of growth factors, activation, viral infection, and some 
chemotherapeutic agents (1).  Immature thymocytes and T 
cell hybridomas die by apoptosis when they were activated 
via the TCR,  as do already activated mature peripheral T 
cells (2-4).  The activation-induced death of thymocytes is 
an important component of negative selection, and therefore 
the establishment of tolerance to self antigens. Activation- 
induced apoptosis of mature T ceils is thought to be at least 
one mechanism of maintaining peripheral tolerance and, per- 
haps, of limiting an ongoing immune response. In addition 
to these physiological examples of T  cell  apoptosis,  inap- 
propriate apoptosis of peripheral T cells from individuals in- 
fected with HIV has been observed, prompting the specula- 
tion that  this phenomenon may play a role in the loss  of 
CD4 + T cells and the immunodeficiency that characterizes 
AIDS (5-9). 
T cell hybridomas have been widely used in the investiga- 
tion of cell death induced by specific antigen or anti-TCR 
antibodies. Activation of T cell hybridomas leads to a rapid 
G1/S cell cycle block (growth arrest), followed by apoptosis, 
which occurs after a period of 4-8 h  (2,  3,  10).  Although 
the mechanism of activation-induced apoptosis is not well 
understood, clues have been gleaned from studies using a va- 
riety of chemical and biological agents. Cycloheximide and 
actinomycin D prevent activation-induced apoptosis in T cell 
hybridomas, indicating a requirement for new protein bio- 
synthesis (10,  11). Inhibitors of T  cell activation and IL-2 
production, such as cyclosporin A (CsA) 1 or depletion of ex- 
tracellular  Ca  2+,  also  block  apoptosis.  Dexamethasone, 
which itself induces apoptosis ofT cell hybridomas and thymo- 
t Abbreviations used in this paper: CsA, cyclosporin  A; Dex, dexamethasone; 
FasL, ligand for Fas. 
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One can distinguish between activation-induced pathways 
leading to IL-2 production or cell death, however, with com- 
pounds such as retinoic acid and protease inhibitors, which 
prevent activation-induced apoptosis but have little effect on 
activation-induced IL-2 production (13-15). 
Another cell surface molecule implicated in lymphocyte 
apoptosis is Fas,  also  known as APO-1 or CD95.  Fas is a 
transmembrane molecule belonging to the TNF/nerve growth 
factor receptor superfamily (16, 17), and its multivalent cross- 
linking with antibody rapidly induces apoptosis in both normal 
and transformed lymphocytes. The ligand for Fas, FasL, has 
recently been identified and cloned (18), and is a type II trans- 
membrane protein that is a member of the TNF superfamily. 
Binding of FasL to Fas results in rapid apoptosis of the Fas- 
expressing cells (18). T  cells from Fas-deficient IFr mice and 
FasL-deficient  gld mice have a defect in antigen-stimulated apop- 
tosis,  strongly supporting the notion that Fas is involved in 
activation-induced T cell apoptosis (19). We have studied the 
requirement for Fas and FasL in the activation-induced cell 
death in T  cell hybridomas, and find that these molecules 
are key components of this process.  Both the requirement 
for cellular activation, and inhibition of death by retinoic acid 
and glucocorticoids, can be explained by the regulated ex- 
pression of FasL  and its interaction with Fas. 
Materials  and Methods 
Cells and Reagents.  2B4.11  is a murine T cell hybridoma specific 
for peptide 81-104 of pigeon cytochrome c (2). 21.2.2 is a variant 
of 2B4.11 that lacks TCR cr  and therefore does not express cell 
surface CD3 (20). PC60-dllS (dllS),  L1210 (leukemia ceil line), 
and L1210-Fas  + (L1210  cells transfected withJas)  cells were kindly 
provided by Dr. P. Golstein (21). Cells were cultured and assayed 
in ILPMI 1640 (Biofluids Inc., Rockville, MD) supplemented with 
10% heat-inactivated FCS, 4 mM glutamine, 100 U/ml penicillin, 
150 #g/ml gentamicin, and 5  x  10 -s M 2-mercaptoethanol. 145- 
2Cll (2Cll) is a hamster monoclonal antibody against mouse CD3-~ 
(22), and was purified from culture supernatant by affinity chro- 
matography with protein A-sepharose. The anti-mouse Fas anti- 
body Jo2 and PE-labeled Jo2 were purchased from PharMingen 
(San Diego, CA),  and PE-anti human  CD8 was purchased from 
(Biosource International,  Camarillo,  CA).  The  anti-mouse  Fc 
receptor antibody 2.4G2 (23) was purified from culture superna- 
tant. Dexamethasone (Dex), PMA, and ionomycin were purchased 
from Sigma Immunochemicals (St. Louis, MO). 9-cis retinoic acid 
was the generous gift of  Dr. R. Heyman (Ligand Pharmaceuticals, 
La Jolla,  CA). 
DNA Fragmentation Assay.  DNA fragmentation  was quanti- 
tated by adherence to fiberglass filters, as described (14). Briefly, 
cells were incubated with [3H]thymidine (5/~Ci/ml) for 3 h and 
then distributed in triplicate into 96-well microtiter plates. Unless 
otherwise indicated, 5  x  104 T cells were plated per well. After 
culture for the indicated times the cells were hypotonically lysed 
and harvested onto fiberglass falters (PHI) Cell Harvester; Cam- 
bridge Technology, Cambridge, MA). Intact chromatin adheres to 
the falters, but DNA fragments pass through. The results are ex- 
pressed as specific DNA fragmentation: 
M-E 
--x  100  M 
where M  =  retained label in cells cultured in medium, and E  = 
retained label in cells cultured under experimental conditions,  _+ 
the standard error of the mean. In cell mixing experiments the 
number of labeled "target" cells was held constant at 2.5  x  104 
cells per well and the number of "effector" cells was varied from 
1.25 x  104 to 1.25  x  105 cells per well. 
IL2 Assay.  Aliquots of supernatant were removed and assayed 
for Ib2 as described (24). An IL-2 unit is defined as the dilution 
of supernatant that caused IL-2-dependent CTLL-2 cells to incor- 
porate half-maximal amounts  of [3H]thymidine. 
Growth Inhibition Assay.  2B4.11 cells were cultured under the 
indicated conditions.  After 16 h,  1 #Ci of [3H]thymidine was 
added to each well. After another 4 h,  the cells were harvested 
and incorporation of radiolabel determined by liquid scintillation 
counting. The data are expressed as the clam incorporated in each 
experimental condition divided by the cpm incorporated by cells 
grown in medium alone. 
Activation of d11S Cells.  d11S cells were activated with PMA 
(10 ng/ml) plus ionomycin (3/zg/ml) for 3 h to induce expression 
of FasL, as described (21). 
Flow Cytometry.  Specific  staining was performed with PE-Jo2. 
Phycoerythrin-conjugated mouse anti-human CD8 was used as a 
negative control. Flow cytometric analysis was performed with a 
FACScan (Becton-Dickinson,  CA). 
Receptor Fc Constructs.  A cDNA encoding the extracellular do- 
main of Fas was isolated by PCR from the II-23.D7 human T cell 
hybridoma (25). This fragment was ligated in frame to a 710-bp 
cDNA fragment encoding the hinge, CH2 and CH3 domains of 
human IgG1 and subcloned into pDC302. For construction of the 
baculovirus transfer vector, a double stranded linker was designed 
with an internal EcoR1 site and a KpnI overhang with the sequence 
5'-CACAATTCGGGTAC-3' and for the bottom strand 5'-CCG- 
AATTCTC-3'. The bottom strand was treated with T4 polynucleo- 
tide kinase before annealing to the linker and subsequent ligation 
to the Fas:Fc KpnI/NotI site of the baculovirus transfer vector, 
pV1393 (Invitrogen, San Diego, CA). The TNFR60:Fc chimera, 
composed  of  the extracellular  domain of the 55-60-kD TNF receptor 
and the Fc portion of human IgG1, was constructed as described 
(26). Tn5B1-4  cells were infected with recombinant baculovirus in 
serum-free medium and the proteins purified to homogeneity by 
affinity chromatography using a protein G-Sepharose 4BCL resin. 
Northern Blot Analysis.  2B4.11 cells (15  x  106 per point) were 
cultured in tissue culture dishes (Falcon 3003; Becton Dickinson 
Labware, Lincoln Park, NJ) that were coated with medium alone 
or anti-CD3 (10/zg/ml). After culture for the indicated  times, RNA 
was prepared by a modified guanidine thiocyanate method (27). 
cDNA of the extracellular portion of mouse  FasL was  kindly 
provided by Dr. B. Niklinska (National Cancer Institute, National 
Institutes of Health,  Bethesda, MD),  and was obtained by PCR 
using the primers GGA ATT CAT GCA GCT CTT CCA GAC 
AGA AGG A and CGG GAT CCT TAA AGC TTA TAC AAG 
CCG AAA AAG, and purified from agarose  gel using the Geneclean 
II kit (Bio 101, Inc., Viata, CA). The Pst fragment of glyceralde- 
hyde 3-phosphate dehydrogenase (GAPDH) was kindly provided 
by Drs. F. Mushinski and L. King (National Cancer Institute, Na- 
tional  Institutes  of Health).  The probes were labeled with 32p 
using the random primer labeling kit from Stratagene (La Jolla, 
CA). 15 #g of total RNA, as determined by UV absorption, was 
loaded into each well and electrophoresed through a 1.0% agarose 
gel. After transfer to nitrocellulose, hybridization was carried out 
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turer (Stratagene Inc., San Diego, CA). After exposure to detect 
FasL, the blots were stripped  twice with boiling 0.1x  SSC and 
0.1%  SDS buffer, and then reblotted  for GAPDH. 
Results 
Characterization of  a "Deathless" Variant  of the 2B4.11 T Cell 
Hybridoma.  Activation of T  cell hybridomas via the TCR 
results in II,-2 production, a Gt/S cell cycle block, and apop- 
tosis (2, 3, 10, 28). There appears to be more than one sig- 
naling pathway for these responses, since activation-induced 
apoptosis and ID2 production require extracellular Ca  2+ and 
are inhibited by CsA, while the cell cycle block does not re- 
quire extracellular Ca  z+ and is CsA resistant (28). In an at- 
tempt to obtain T  cell hybridoma variants that  do not die 
when activated, 2B4.11  T  hybridoma cells were cultured at 
a density of 104 per microtiter well with 5  x  105 B10.A ir- 
radiated spleen cells (as a source of antigen-presenting cells) 
and 30/zM pigeon cytochrome c fragment 81-I04. As shown 
in Fig. 1, cells that grew from one well, termed VD1 cells, 
did not die when restimulated with  anti-CD3  (Fig.  1 A). 
VD1 cells also did not  die when  the antigen  for which it 
is specific, pigeon cytochrome c, was used as a stimulus (data 
not shown). In contrast to the failure to undergo activation- 
induced apoptosis, stimulation of VD1 cells with anti-CD3 
resulted in two other discrete biological responses that were 
quantitatively indistinguishable from those of the wild-type 
cells: IL-2 production and growth inhibition, the latter being 
mainly a manifestation of the G1/S cell cycle block (Fig.  1, 
B and C) (28). Therefore, although biological responses that 
are  mediated  by  several  distinct  TCR-mediated  signaling 
pathways are intact in VD1 cells,  activation-induced  apop- 
tosis is not. 
Analysis of  Fas in 2B4.11 and VDI Cell.  2B4.11 and VD1 
cells were analyzed for a variety of functionally important 
cell surface molecules, and were found to express comparable 
levels TCR, Ly-6, Thy-1, CD45, CD4, and CD8 (both cells 
being negative for the latter two).  There was a difference, 
however, in expression of Fas. As shown in Fig. 2, unacti- 
vated 2B4.11 cells expressed easily detectable levels of Fas, with 
virtually all of the cells constituting  a distinct peak in the 
fluorescence profile. No change in Fas expression was detected 
1, 2, 4, or 6 h after anti-TCR activation of 2B4.11 cells (data 
not shown). Although positive, VD1 cells were very dull for 
Fas compared to the staining control.  For comparison,  Fas 
expression  on  L1210  cells,  which  are  insensitive  to  FasL- 
mediated killing,  and L1210-Fas  cells, which die when cul- 
tured with FasDbearing effector cells (21), was determined. 
L1210 cells are heterogeneous for Fas expression, with roughly 
half the cells appearing to be negative and the other half ex- 
pressing variable amounts of Fas (Fig. 2). L1210-Fas cells are 
uniformly positive for Fas, with a mean fluorescence inten- 
sity approximately twice that  of 2B4.11 cells. 
Since Fas is a receptor that  transduces  signals  leading to 
death, we asked how 2B4.11 and VD1 ceils would respond 
when cultured with FasL + effector cell.  d11S is a subclone 
of a rat-mouse T  cell hybridoma whose expression of cell 
surface FasL  increases  after activation with PMA and ion- 
omycin (21). As previously shown (21), unactivated d11S caused 
a small amount of apoptosis in 2B4.11 cells,  and its activa- 
tion with PMA and ionomycin greatly enhanced this activity 
(Fig.  3 A).  The killing was mediated by Fas, since the Jo2 
anti-Fas monoclonal antibody blocked the killing of the 2B4.11 
cells  (note that  soluble Jo2 does not kill 2B4.11  cells  since 
it is an IgG,  and bivalent binding  of Fas is insufficient  to 
induce death [29]). In contrast to 2B4.11 cells, VD1 cells were 
not killed by d11S, even when the effector cells  were acti- 
vated with PMA and ionomycin (Fig.  3 B).  Thus, just as 
when they are activated via the TCR, VD1 cells do not die 
when  signaled  through  Fas. 
Activation-induced Death of T Cell Hybridoma Is Blocked by 
Anti-Fas Antibody and Soluble Fas Protein.  The failure of VD1 
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Figure 1.  Activation of VD1 cells results  in growth arrest and IL-2 production but not DNA fragmentation. [3H]Thymidine-labeled  2B4.11 and 
VD1 cells were stimulated with plastic-coated anti-CD3 antibody in microtiter wells for t8 h, and the percentage  DNA fragmentation determined 
(A). Unlabeled cells were cultured in parallel under identical conditions and after 18 h assessed for IL-2 production (B) and incorporation of [3H]thymidine 
(C). -O-,  2B4.11; -O-,  VD1. 
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Figure  2.  Flow cytometric analysis of Fas expression on 2B4.11, VD1, 
L1210, and L1210-Fas calls.  106 cells were incubated with the anti-mouse 
Fc receptor antibody 2.4G2 and then stained with either PE-labded anti- 
mouse Fas antibody Jo2 (solid line) or PE-labeled anti-human CD8 anti- 
body (dashed line). 
cells to be killed by FasL-bearing effector cells raised the pos- 
sibility that activation-induced death, to which VD1 is resis- 
tant, is mediated by Fas. To determine if Fas is involved in 
activation-induced apoptosis, the Jo2 anti-Fas antibody was 
added to 2B4.11 cells that were or were not activated with 
anti-CD3 (Fig. 4).  Immobilized anti-CD3 antibody alone 
caused -035%  specific DNA fragmentation of 2B4.11 cells. 
The activation-induced DNA fragmentation was completely 
prevented by anti-Fas antibody in a dose-dependent fashion, 
with complete inhibition achieved at 150 ng/ml (Fig. 4 A). 
In contrast to its inhibition of apoptosis,  the Jo2 antibody 
had no effect on activation-induced IL-2 production (Fig. 4 
B). Glucocorticoids also induce apoptosis in T  cell hybrid- 
omas, but by a pathway that is distinct from that of activa- 
tion (12). To determine the specificity of anti-Fas inhibition 
of apoptosis, Jo2 was added to 2B4.11 cells treated with in- 
creasing concentrations of Dex (Fig. 4 C). Unlike activation 
via the TCR, addition of anti-Fas antibody had no effect on 
DNA fragmentation caused by Dex. Another response to ac- 
tivation, growth arrest, was also measured. Anti-Fas anti- 
bodies did not prevent activation-induced inhibition of trans- 
formed growth (Fig.  5). Together with the failure to block 
IL-2 production, these results indicate that anti-Fas did not 
interfere with activation per se, just with the apoptotic re- 
sponse  to activation. 
Another means of  blocking an interaction between Fas and 
FasL is to use a soluble form of Fas to bind the FasL on the 
effector cells. A chimeric molecule consisting of the extracel- 
lular region of human Fas and the Fc portion of human IgG1 
(Fas:Fc) has been generated. Given that mouse and human 
Fas and FasL bind to one another (30), we asked what effect 
50- 
o 
40- 
O 
30- 
~  2o- 
~  10- 
B 
4:1  2:1  1:1  0.5:1 
dUS  : T  Hybridoma Ratio 
Figure  3.  2B4.11 cells but not VD1 cells are sensitive to Fas-mediated 
killing. [3H]Thymidine-labeled 2B4.11  cells with or without anti-Fas Jo2 
(250 ng/ml) (A) or 2B4.11 and VD1 cells (B) were cocnltured with acti- 
vated or unactivated d11S cells at the indicated cell ratios, and DNA frag- 
mentation measured 6 h later. (.4) --[3-, unactivated d11S; -I--,  unacti- 
vated d11S  +  Jo2; --O--, activated d11S; --~-,  activated d11S  +  Jo2. (B) 
-C]--,  2B4.11  +  unactivated d11S; --I~,  2B4.11  activated d11S;  --O% 
VD1  +  unactivated d11S;  +,  VD1  +  activated d11S. 
this soluble molecule would have on activation-induced T 
cell apoptosis (Fig.  6).  Anti-CD3 induced ,,o55%  specific 
DNA fragmentation, which was inhibited by soluble Fas:Fc 
in a concentration-dependent manner, with maximal inhibi- 
tion achieved at 10/zg/ml. As a control, a chimeric molecule 
consisting of the extracellular portion of the Fas-related TNF 
receptor and the Fc portion of human IgG1 (TNFP~60:Fc) 
was added to activated 2B4.11 cells. Unlike Fas:Fc, this mol- 
ecule had no effect on activation-induced death. The effect 
of Fas:Fc on T  cell death was stimulation specific, in that 
glucocorticoid-induced apoptosis  was unaffected by Fas:Fc, 
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Figure  4.  Effect of anti-Fas on killing of activated or glucocorticoid-treated  T cell hybridomas.  (A) [3H]Thymidine-labeled  2B4.11 cells (5  x  104 
per well) were cultured in microtiter wells that had not ([~) or that had (ll) been coated with anti-CD3 (1 #g/well). Jo2 was added at the indicated 
concentrations,  and DNA fragmentation measured  18 h later. --U]-, medium; --B-, anti-CD3. (B) Supernatant  from unlabeled 2B4.11 cells cultured 
as in (A) was removed after 4 h and assayed for IL-2. (C) Labeled 2B4.11 cells (5  x  104) were cultured with the indicated  concentrations  of Dex 
in the absence (El) or presence (.)  of Jo2 (150 ng/ml). ~,  medium; --IF, anti-Fas. 
even at a concentration  of 20 #g/ml.  As with the anti-Fas 
antibody, Fas:Fc did not prevent activation-induced growth 
inhibition  or IL-2 production  (data  not  shown). 
Expression of  Fas and FasL on T Cell Hybridomas.  FasL has 
been reported  to be highly expressed on activated but not 
resting T cells (18). Since Fas itself is constitutively expressed 
on 2B4.11 cells and its levels were unaffected by activation, 
it seemed likely that  the activation-regulated  expression of 
FasL might  account for the apoptotic response to stimula- 
tion via the TCK.  FasL mRNA expression was measured 
by Northern blot analysis.  No FasL mRNA was detected in 
unstimulated  2B4.11  cells (Fig.  7 A).  However, as early as 
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Figure  5.  Anti-Fas does not prevent activation-induced  growth inhibi- 
tion. 2B4.11 cells (2.5  x  104 per well) were incubated  in wells coated 
with the indicated  concentrations  of anti-CD3 or medium alone in the 
absence ([]) or presence (11) of Jo2 (250 ng/ml). The data are expressed 
as percent inhibition of growth compared to cells cultured in the absence 
of anti-CD3. In this experiment,  anti-CD3 caused 53.0% specific DNA 
fragmentation;  anti-CD3 plus anti-Fas (250 ng/ml) induced 0.9% specific 
DNA fragmentation.  --{Z-, medium; -tl-  anti-Fas. 
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2 h after anti-TCR mediated activation,  a small amount of 
FasL mRNA was detected (the FasL band at 2 h is readily 
detected on longer exposure of the blot). The level of FasL 
mRNA continued to increase up to 4-6 h. FasL mKNA levels 
were not assessed beyond this time point because of the in- 
creasing amount of cell death, which is accompanied by degra- 
dation of KNA (31),  in these activated cultures.  To deter- 
mine  if the  increase  in  FasL  mKNA  was reflected in  the 
expression of functional cell surface FasL, the ability of acti- 
vated 2B4.11 cells to induce Fas-mediated cell death was as- 
sessed (Fig.  8). Unactivated 2B4.11  cells did not kill either 
L1210 cells or L1210-Fas cells. However, 2B4.11 cells that had 
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Figure 6.  Soluble Fas:Fc prevents activation-  but not glucocorticoid- 
induced apoptosis. Labeled 2B4.11 cells (5  x  10  s per well) were cultured 
in medium, wells coated with anti-CD3 (1 #g/well), or in medium con- 
taining Dex (10- 7 M) in the presence of the indicated concentrations  of 
either Fas:Fc or TNFR60:Fc. DNA fragmentation  was assessed after 18 h 
of culture. The standard errors of the mean were ~5% for each experimental 
point.  -Ck-,  medium  +  Fas:Fc; ~  anti-CD3  +  Fas:Fc;  -O-, 
medium  +  TNFR60:Fc;--0-, anti-CD3  +  TNFR60:Fc; ~-,  Dex + 
Fas:Fc. Figure  7.  Northern blot analysis  of FasL expression  in 2B4.11 cells. (A) 
RNA was prepared from 2B4.11 cells cultured for the indicated times in 
plates coated with anti-CD3. (B) RNA was prepared from 2B4.11 cells 
cultured for 6 h in the presence of either 9-c/s retinoic acid (10 -6 M) or 
Dex (10-6 M). The cells were cultured in plates that had or had not been 
coated with anti-CD3, as indicated. The 6 h time point in A represents 
the amount of FasL induced  in the absence  of  these reagents. After probing 
with 32p-labeled FasL cDNA,  the blot was stripped and reprobed with 
32p-labeled  GAPDH cDNA. FasL  is ",,2 kb, and is indicated  by the arrow. 
been activated by immobilized anti-CD3 specifically lysed the 
Fas + L1210-Fas cells, but not the Fas-  L1210 cells,  in a dose- 
dependent manner (Fig. 8). Thus,  activated 2B4.11 cells ex- 
press  functional FasL. 
Since 2B4.11  cells express Fas constitutively and are sus- 
ceptible  to  killing  by  FasL +  dlls  cells,  one would  expect 
that activated, FasL + 2B4.11 cells would cause the death of 
unactivated  2B4.11  bystander cells.  To test  this,  we used a 
variant of 2B4.11,  21.2.2,  that does not express cell surface 
TCR because it lacks TCR oe and 3  chains (20). As shown 
in Fig.  9 A,  2B4.11 but not 21.2.2 cells died in a stimulus- 
dependent manner when cultured in wells coated with anti- 
CD3  antibodies.  As  shown  for  2B4.11,  TCR-  21.2.2  are 
also susceptible to Fas-mediated killing, since coculture with 
d11S cells resulted in their death, which was inhibited by anti- 
Fas antibodies (Fig. 9 B). In Fig. 9 C, unlabeled 2B4.11 cells 
were cultured with labeled 21.2.2 cells for 16 h  in the pres- 
ence of anti-CD3.  As the amount of anti-CD3  per well in- 
creased there was a corresponding increase in specific DNA 
fragmentation of 21.2.2  cells.  This  cell death required Fas, 
since the Jo2 anti-Fas antibody blocked 21.2.2 cell death in 
this mixed culture.  Thus,  activated, FasL §  2B4.11 cells can 
kill unactivated bystander cells via a Fas-dependent mechanism. 
Retinoic Acid and Dexametkasone Prevent Activation-induced 
FasL Up-regulation.  Both retinoic acid, especially the 9-c/s 
stereoisomer, and glucocorticoids inhibit activation-induced 
apoptosis of T  cell hybridomas  (12-14).  Experiments were 
performed to determine if the biological activity of either 
of these reagents is due to effects on the regulation of FasL 
expression. 9-C/s retinoic acid completely prevented, and Dex 
greatly  reduced,  the  activation-induced  increase  in  FasL 
mRNA in 2B4.11 cells (Fig.  7 B).  These decreases in FasL 
mRNA were reflected in the biological activity of this mole- 
cule, since 2B4.11 cells that were stimulated with anti-CD3 
antibody in  the presence of 9-c/s retinoic acid  (10 -6 M)  or 
Dex (1 #M) did not induce the death of L1210-Fas cells (Fig. 
10).  This effect on cytotoxicity was  at  the level of effector 
2B4.11 cell generation, because addition of retinoic acid or 
Dex to L1210-Fas cells at the time of adding activated 2B4.11 
cells had  no  effect on  Fas-mediated cell death  (Fig.  10). 
80- 
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Figure 8.  Activated  VD1 cells  express  FasL. 2B4.11 or VD1 cells (5 x 
104/well) were cultured for 4 h in the presence  of the indicated amounts 
of anti-CD3. After 4 h, [3H]thymidine-labeled  L1210 or L1210-Fas  cells 
(5  x  104/well)  were added. After another 6 h of culture, DNA fragmen- 
tation of the labeled cells was determined. There was no specific  DNA 
fragmentation detected when L1210  cells or L1210-Fas  cells were cultured 
in parallel under identical conditions except that no T cell hybridomas 
were present (data not shown). -C]-, 2B4.11 +  L1210;  -l-,  2B4.11 + 
L1210-Fas; -O--, VD1  +  L1210; -4~,  VD1  +  L1210-Fas. 
Discussion 
Fas  is a 48-kD  transmembrane molecule that belongs  to 
the  TNF/nerve  growth  factor  receptor  gene  superfamily, 
which also includes  CD27,  CD40,  CD30,  and OX40  (16, 
17,  32).  Mouse  Fas  mRNA  is expressed in  thymus,  liver, 
heart, lung,  and  ovary; it  is undetectable  in  spleen,  brain, 
kidney, and bone marrow (32).  Fas is not expressed by the 
majority of human peripheral blood T  cells unless they have 
been activated (33-35).  It is expressed at high levels on hu- 
man  CD4 +  CD8 +  TCR  intermediate thymocytes, decreasing in 
level as the cells mature to the TCR  hi stage (36). Two groups 
independently identified Fas as a signaling molecule whose 
cross-linking with antibody can lead to death (33, 37). Until 
recently little was  known  about  how ligation  of Fas leads 
to death. Mutational analysis has shown that an intracellular 
domain that is homologous to a region in the TNF receptor 
is required for Fas-mediated killing (29). However, the intra- 
cellular portion of the molecule has no consensus sequences 
for kinases or phosphatases. It has recently been demonstrated 
that cross-linking of Fas on a variety of human cell lines in- 
duces the activity of an acid sphingomyelinase, which results 
in the generation of ceramide, and that exogenous addition 
of the cell-permeable C2-ceramide induces apoptosis in these 
cells (38). This mechanism has also been suggested for cell 
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Figure  9.  Activated 2B4.11 cells kill unactivated bystander cells by a Fas-dependent mechanism. (A) Labeled 2B4.11 (O) or VD1 (0) cells (2.5 x 
104/well) were cultured for 16 h in the presence of the indicated concentrations of anti-CD3 and then assayed for DNA fragmentation. (B) Labeled 
21.2.2 cells were cultured with  activated d11S cells at the indicated cell ratios for 16 h in the absence (O) or presence (Q) of Jo2 (250 ng/ml), at 
which time DNA fragmentation was measured. (C) Unlabeled 2B4.11 (5  x  104/well) were cultured with equal numbers of [3H]thymidine-labeled 
21.2.2 cells in the presence of the indicated concentrations of anti-CD3 and without  (O) or with  (O) Jo2 (250 ng/ml).  After 16 h the cells were 
assayed for DNA fragmentation. Standard errors were typically ~<5% for each experimental point. 
death mediated by the TNF receptor (39).  How ceramides 
might initiate a program leading to cell death remains to be 
elucidated. 
FasL has recently been identified (18). The FasL gene en- 
codes a transmembrane  protein with  a predicted molecular 
mass of 31 kD. The molecular mass of the expressed mole- 
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Anti-CD3 treatment of 2B4.11 cells (~tg/well) 
Figure  10.  Retinoic  acid and glucocorticoids  block expression of func- 
tional FasL on activated T cell hybridomas. 2B4.11 cells (5  x  104/well) 
were cultured in wells coated with the indicated amounts of anti-CD3 
without or with 10 -6 M Dex (Q) or 10 -6 M 9-c/s retinoic acid (A). After 
6 h,  [3H]thymidine-labeled L1210 or L1210-Fas cells (2.5  x  104) were 
added to these wells. In some cases, 10 -6 M Dex (O) or 10 -6 M 9-cis 
retinoic acid (A) was added to wells that initially contained medium alone. 
After 4 h of coculture the amount of DNA fragmentation of the labeled 
cells was measured. The parentheses in the boxed legend indicate at what 
time, in the first culture or in the mixed cell culture, Dex or retinoic acid 
was added. The standard errors of the  mean were ~5% for each ex- 
perimental point.  --[~,  2B4  +  L1210-Fas; ~,  2B4 L1210; -4~, 
(2B4 +  Dex)  +  L1210-Fas; ~,  (2B4 +  RA)  +  L1210-Fas; --O--, 
2B4 +  (Dex +  L1210-Fas);--Lk-,  2B4  +  (RA  +  L1210-Fas). 
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cule is 38,000-42,000, the larger molecular size probably being 
due to N-linked glycosylation. FasL is homologous to the 
TNF family of molecules. Cells transfected with FasL cDNA, 
but not control cells,  were able to kill Fas + targets.  Interest- 
ingly, supernatants of COS cells transfected with FasL cDNA 
were also able to kill Fas + targets,  suggesting that FasL can 
be shed in an active form. Rat FasL mRNA has a very different 
tissue distribution from Fas, being expressed in small intes- 
tine,  testis,  lung,  and spleen.  Of particular  interest  is  that 
activation of spleen cells or thymocytes induces expression 
of FasL,  indicating  that  activated T  cells can express both 
Fas and FasL (18).  Human and mouse FasL are highly ho- 
mologous, and human and mouse FasL bind to Fas from ei- 
ther  species  (30). 
Our data demonstrate that, as for the majority of thymo- 
cytes, the 2B4.11 T  cell hybridoma constitutively expresses 
Fas, and cellular activation induces expression of FasL. The 
interaction of this receptor-ligand pair is required for activation- 
induced apoptosis of these cells. VD1 cells, which were selected 
by virtue  of their  resistance  to  TCR-mediated  activation- 
induced death, have very low levels of Fas but normal levels 
of functional FasL upon activation. We believe that the low 
level of Fas on VD1 is sufficient to account for its resistance 
to FasL- or activation-induced death,  since the level of Fas 
on these cells is comparable to, or even less than,  the levels 
of Fas on L1210 cells. It is possible, however, that in addition 
to lower than normal expression,  Fas may be mutated and 
nonfunctional in VD1 cells, or there may be defects in other 
components of the Fas-mediated signaling pathway. Further 
evaluation of Fas and its signaling pathway(s) in VD1 cells 
should allow us to distinguish  between  these  possibilities. 
Pharmacological agents such as retinoic acid and glucocor- 
ticoids are able to block activation-induced apoptosis of T 
cells.  The data in the present paper show that both of these agents prevent the up-regulation of FasL, but have no effect 
on killing signaled through Fas by effector cells that are al- 
ready FasL +. Both of these molecules mediate their effects 
by binding  ligand-regulated nuclear transcription  factors. 
Therefore, the simplest mechanism by which they might affect 
FasL expression would be for their respective receptors/tran- 
scription factors to directly regulate FasL gene transcription. 
An analysis  of '-300 bp 5' of the ATG initiation codon of 
human FasL has found regulatory elements for SP-1, NF-KB, 
and IRF-1 (30). There are no obvious retinoic acid response 
elements or glucocorticoid response elements in this region. 
Such response elements may be found in more distal flanking 
regions of the gene, or possibly in intronic sequences. Alter- 
natively, glucocorticoids and/or retinoic acid may exert their 
effects on FasL by an indirect mechanism. We have also found 
that CsA, which prevents Ca2+-dependent activation events 
by inhibiting the phosphatase calcineurin (40, 41) and inhibits 
activation-induced  apoptosis  but  not  the  G1/S  cell  cycle 
block (28), also prevents activation-induced up-regulation of 
FasL (our unpublished observation). Therefore, a variety of 
agents that mediate their protective effects by interacting with 
different DNA-regulatory sites or proteins have in common 
the ability to suppress  FasL expression. 
In the present study we found that activated 2B4.11 cells 
were able to kill unactivated 2B4.11 cells in a Fas-dependent 
manner. We have previously shown that when T cell hybrid- 
omas with different antigen specificities are cocultured in the 
presence of one antigen, only the growth of the activated 
cell is inhibited (2).  That is consistent with the finding in 
the present report in that the GffS block induced by activa- 
tion does not seem to be Fas dependent: unlike apoptosis, 
growth inhibition was not reversed by anti-Fas  antibodies. 
Another study, in which only one of two cocultured T cell 
hybridomas was specifically activated, detected only a small 
amount of bystander killing (of 2B4.11 cells) as measured by 
release of fragmented DNA, which was interpreted as indi- 
cating a lack of bystander killing (10). However, in that ex- 
periment the total time of stimulation was only 8 h, com- 
pared to 16 h of coculture in the present report. FasL must 
be up-regulated before activated cells can act as effectors, and 
by Northern blot analysis it takes 4-6 h to achieve high levels 
of expression. We have found that at shorter times of cocul- 
ture Fas-dependent bystander killing is more difficult to de- 
tect (data not shown), indicating that killing in trans may 
be less effident that killing in cis. This may be because Fas-FasL 
interactions are more effective if both molecules are present 
on the same cell. Alternatively, just as with FasL-expressing 
COS cells (18),  FasL may be shed from activated cells and 
preferentially interact with Fas molecules on the same cell. 
The biological importance of Fas and FasL in normal T 
cell biology is demonstrated by the phenotypes of lpr and 
gld mice, which have defects in expression of Fas and FasL, 
respectively (42, 43). The major pathological changes in these 
mice are accumulation of CD4-CD8- TCR + T cells (lym- 
phoproliferation) and autoimmunity (44).  It has been sug- 
gested that the accumulating aberrant T cells originate from 
"neglected" CD4 +  CD8 +TCR auu thymocytes that escape to 
the periphery due to absence of Fas (45). However, although 
the thymus expresses the highest level of Fas mRNA among 
normal tissues,  and activation of thymocytes induces FasL 
mRNA, the development of thymocytes appears to be normal 
in lpr mice (46,  47). More recently, using transgenic TCR 
crossed with MRL-lpr/1pr or control MRL  +/+  mice, it has 
been possible to demonstrate a role for Fas in peripheral but 
not thymic deletion of T  lymphocytes (48).  This observa- 
tion is supported by experiments that show activation-induced 
apoptosis of peripheral T cells depends on Fas and FasL (19, 
49-51). Thus, at this time, it appears  that Fas/FasL plays a 
critical role in peripheral T cell deletion, It is interesting to 
note that degree of T cell hybridoma apoptosis induced with 
a mitogenic anti-Thy-1 antibody varies  with the maturity 
of the T cell fused to the BW5147 murine thymoma: fusions 
made with immature thymocytes are resistant to killing, while 
those made with peripheral T  cells are sensitive  (11). This 
may suggest that the T ceil hybridoma phenotype, with re- 
gard to activation-induced apoptosis at least, reflects a pathway 
present in mature, but not immature, T cells, which is con- 
sistent with our present understanding of the biological role 
of Fas and FasL in regulated T  cell death. 
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